Companies › Bausch & Lomb
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 4; Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Miebo (Perfluorohexyloctane Ophthalmic Solution) Perfluorocarbon ocular surface protectant; creates hydrophobic barrier on cornea to reduce | – | Phase 4 | Dry Eye | – |
| BL1332 ophthalmic solution | – | Phase 1 | Ocular Pain | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06565650 | Miebo (Perfluorohexyloctane Ophthalmic Solution) | Phase 4 | Dry Eye | Ophthalmology | Nov 2025 |
| NCT06978244 | BL1332 ophthalmic solution | Phase 1 | Ocular Pain | Ophthalmology | Nov 2026 |
Cash of $513m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
No annotated target.
–
Glaukos Huons PolyActiva Taejoon Pharmaceutical Belite Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.